The price of Immix Biopharma Inc. (NASDAQ:IMMX) shares last traded on Wall Street fell -8.24% to $2.34.
Based on available information, 1 analysts follow Immix Biopharma Inc. (NASDAQ:IMMX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $5.00, we find $5.00. Given the previous closing price of $2.55, this indicates a potential upside of 96.08 percent. IMMX stock price is now 64.00% away from the 50-day moving average and 26.56% away from the 200-day moving average. The market capitalization of the company currently stands at $35.50M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $5.00 as their price target over the next twelve months.
.
In other news, Rachman Ilya M, CEO and Chairman bought 5,200 shares of the company’s stock on Nov 14. The stock was bought for $5,225 at an average price of $1.00. Upon completion of the transaction, the CEO and Chairman now directly owns 907,700 shares in the company, valued at $2.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 14, CFO Morris Gabriel S bought 5,200 shares of the business’s stock. A total of $4,888 was incurred on buying the stock at an average price of $0.94. This leaves the insider owning 81,316 shares of the company worth $0.19 million. Insiders disposed of 400 shares of company stock worth roughly $936.0 over the past 1 year. A total of 13.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in IMMX stock. A new stake in Immix Biopharma Inc. shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $63,000. NORTHERN TRUST CORP invested $45,000 in shares of IMMX during the first quarter. In the first quarter, TOWER RESEARCH CAPITAL LLC (TRC) acquired a new stake in Immix Biopharma Inc. valued at approximately $1,000. In total, there are 7 active investors with 2.20% ownership of the company’s stock.
A candlestick chart of Immix Biopharma Inc. (NASDAQ: IMMX) showed a price of $2.2500 on Friday morning. During the past 12 months, Immix Biopharma Inc. has had a low of $0.68 and a high of $7.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 26.90, and a quick ratio of 26.90. The fifty day moving average price for IMMX is $1.4519 and a two-hundred day moving average price translates $1.8495 for the stock.
The latest earnings results from Immix Biopharma Inc. (NASDAQ: IMMX) was released for Jun, 2022. The company reported revenue of $1.53 million for the quarter, compared to $0.35 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 340.52 percent.
Immix Biopharma Inc.(IMMX) Company Profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn’s disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
